formulations such as matrix tablets or multiparticulate formulations like micro capsules or coated pellets put into hard gelatin capsules this provides effective drug delivery for extended periods of time at relatively stable optimal plasma peak values with minimal undesirable side effects the invention provides effective controlled extended release oral dosage formulations of chromium picolinate and processes for their preparation application_number US 1016598 A description the present invention relates to oral controlled extended release dosage form of chromium picolinate applying either to matrix formulations such as matrix tablets or multiparticular formulations like micro capsules or coated pellets put into hard gelatin capsules this is done in order to obtain a drug delivery system of chromium picolinate which will ensure a constant supply of the active ingredient during the day by either embedding the chromium picolinate into a matrix formulation or incorporating it into a microcapsule formulation or both in order to control or extend the release the following advantages are obtained compared to when conventional immediate release formulations are used a slower in vivo absorption of chromium and hence optimal plasma peak values which hence reduce the occurrence of undesired side effects prolonged and constant chromium plasma concentrations over 24 hours which will avoid underdosing between dosage intervals a significant increase of the relative extent of chromium bioavailability i e the therapeutically relevant component much higher tolerability of the drug i e much less side effects a once daily dosing which together with the higher tolerability definitely will significantly increase the patient compliance in general the formation of microencapsulated material and matrix adjuvant is known in the art as coating or matrix adjuvant any coating or matrix material can be used the type of material used will be chosen depending on the desired controlled release time.